This episode examines high impact neurology regulatory decisions scheduled for the first half of twenty twenty six, including tolebrutinib for non-relapsing secondary progressive multiple sclerosis, GTx one oh four for aneurysmal subarachnoid hemorrhage, tavapadon for Parkinson disease, and once weekly subcutaneous lecanemab for early Alzheimer disease. It reviews FDA authorizations for women’s health therapeutics and diagnostics in twenty twenty five, including gepotidacin, Sonio Suspect, Visby Medical’s at home STI test, and the Teal Wand for cervical cancer screening. The briefing covers the operational shift from AI experimentation to enterprise scale deployment in healthcare, focusing on ambient listening integration, revenue cycle automation, and agentic AI in clinical workflows. It concludes with BioAtla’s forty million dollar special purpose vehicle transaction with GATC Health and Inversagen AI to advance ozuriftamab vedotin into registrational Phase Three trials for oropharyngeal squamous cell carcinoma.
